PURPOSE: To assess Prostate Imaging and Data Reporting System (PI-RADS) v. 2 score 4/5 lesions compared to Gleason score (GS) and stage after radical prostatectomy (RP) and to validate the proposed 15-mm size threshold that differentiates category 4 versus 5 lesions. MATERIALS AND METHODS: With Institutional Review Board (IRB) approval, 140 men underwent 3T magnetic resonance imaging (MRI) and RP between 2012-2015. Two blinded radiologists: 1) assigned PI-RADS v. 2 scores, 2) measured tumor size on axial T2 -weighted-MRI, and 3) assessed for extraprostatic extension (EPE). Interobserver agreement was calculated and consensus diagnoses achieved through reference standard (MRI-RP maps). PI-RADS v. 2 scores and tumor size were compared to GS and stage using chi-square, analysis of variance (ANOVA), and receiver operating characteristic (ROC) curve analysis. RESULTS: In all, 80.7% (113/140) of tumors were category 4 (n = 45) or 5 (n = 68) lesions (κ = 0.45). Overall tumor size was 18.2 ± 7.7 mm and category 5 lesions were larger (22.6 ± 6.8 versus 11.5 ± 1.9 mm, P < 0.001). High-risk (GS ≥8) tumors were larger than low- and intermediate-risk tumors (P = 0.016) and were more frequently, but not significantly so, category 5 lesions (78.9% [15/19] vs. 22.1% [4/10], P = 0.18). 67.3% (76/113) of patients had EPE. Category 5 lesions were strongly associated with EPE (P < 0.0001). Area under the ROC curve for diagnosis of EPE by size was 0.74 (confidence interval 0.64-0.83), with size ≥15 mm yielding a sensitivity/specificity of 72.4/64.9%. Size improved sensitivity for diagnosis of EPE compared to subjective assessment (sensitivity/specificity ranging from 46.1-48.7%/70.3-86.5%, κ = 0.29) (P = 0.028). CONCLUSION: PI-RADS v. 2 category 5 lesions are associated with higher Gleason scores and EPE. A 15-mm size threshold is reasonably accurate for diagnosis of EPE with increased sensitivity compared to subjective assessment. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:257-266.
PURPOSE: To assess Prostate Imaging and Data Reporting System (PI-RADS) v. 2 score 4/5 lesions compared to Gleason score (GS) and stage after radical prostatectomy (RP) and to validate the proposed 15-mm size threshold that differentiates category 4 versus 5 lesions. MATERIALS AND METHODS: With Institutional Review Board (IRB) approval, 140 men underwent 3T magnetic resonance imaging (MRI) and RP between 2012-2015. Two blinded radiologists: 1) assigned PI-RADS v. 2 scores, 2) measured tumor size on axial T2 -weighted-MRI, and 3) assessed for extraprostatic extension (EPE). Interobserver agreement was calculated and consensus diagnoses achieved through reference standard (MRI-RP maps). PI-RADS v. 2 scores and tumor size were compared to GS and stage using chi-square, analysis of variance (ANOVA), and receiver operating characteristic (ROC) curve analysis. RESULTS: In all, 80.7% (113/140) of tumors were category 4 (n = 45) or 5 (n = 68) lesions (κ = 0.45). Overall tumor size was 18.2 ± 7.7 mm and category 5 lesions were larger (22.6 ± 6.8 versus 11.5 ± 1.9 mm, P < 0.001). High-risk (GS ≥8) tumors were larger than low- and intermediate-risk tumors (P = 0.016) and were more frequently, but not significantly so, category 5 lesions (78.9% [15/19] vs. 22.1% [4/10], P = 0.18). 67.3% (76/113) of patients had EPE. Category 5 lesions were strongly associated with EPE (P < 0.0001). Area under the ROC curve for diagnosis of EPE by size was 0.74 (confidence interval 0.64-0.83), with size ≥15 mm yielding a sensitivity/specificity of 72.4/64.9%. Size improved sensitivity for diagnosis of EPE compared to subjective assessment (sensitivity/specificity ranging from 46.1-48.7%/70.3-86.5%, κ = 0.29) (P = 0.028). CONCLUSION: PI-RADS v. 2 category 5 lesions are associated with higher Gleason scores and EPE. A 15-mm size threshold is reasonably accurate for diagnosis of EPE with increased sensitivity compared to subjective assessment. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:257-266.
Authors: Susan John; Steven Cooper; Rodney H Breau; Trevor A Flood; Ilias Cagiannos; Luke T Lavallee; Christopher Morash; Joseph O'sullivan; Nicola Schieda Journal: Can Urol Assoc J Date: 2018-06-19 Impact factor: 1.862
Authors: Lars A R Reisæter; Ole J Halvorsen; Christian Beisland; Alfred Honoré; Karsten Gravdal; Are Losnegård; Jan Monssen; Lars A Akslen; Martin Biermann Journal: Radiol Imaging Cancer Date: 2020-01-17
Authors: Matthew D Greer; Joanna H Shih; Nathan Lay; Tristan Barrett; Leonardo Bittencourt; Samuel Borofsky; Ismail Kabakus; Yan Mee Law; Jamie Marko; Haytham Shebel; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronald M Summers; Peter L Choyke; Baris Turkbey Journal: AJR Am J Roentgenol Date: 2019-03-27 Impact factor: 3.959
Authors: Sonia Gaur; Stephanie Harmon; Sherif Mehralivand; Sandra Bednarova; Brian P Calio; Dordaneh Sugano; Abhinav Sidana; Maria J Merino; Peter A Pinto; Bradford J Wood; Joanna H Shih; Peter L Choyke; Baris Turkbey Journal: J Magn Reson Imaging Date: 2018-03-31 Impact factor: 4.813
Authors: Nancy N Wang; Richard E Fan; John T Leppert; Pejman Ghanouni; Christian A Kunder; James D Brooks; Benjamin I Chung; Geoffrey A Sonn Journal: Res Rep Urol Date: 2018-11-22
Authors: Ran Kim; Chan Kyo Kim; Jung Jae Park; Jae Hun Kim; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee Journal: Korean J Radiol Date: 2019-02 Impact factor: 3.500